The evidence for pharmacological treatment of neuropathic pain

@article{Finnerup2010TheEF,
  title={The evidence for pharmacological treatment of neuropathic pain},
  author={Nanna Brix Finnerup and S{\o}ren H. Sindrup and Troels Staehelin Jensen},
  journal={PAIN},
  year={2010},
  volume={150},
  pages={573-581}
}
&NA; Randomized, double‐blind, placebo‐controlled trials on neuropathic pain treatment are accumulating, so an updated review of the available evidence is needed. Studies were identified using MEDLINE and EMBASE searches. Numbers needed to treat (NNT) and numbers needed to harm (NNH) values were used to compare the efficacy and safety of different treatments for a number of neuropathic pain conditions. One hundred and seventy‐four studies were included, representing a 66% increase in published… Expand

Paper Mentions

Observational Clinical Trial
The aim of this study is to evaluate the efficacy of oral administration of nabilone or THC/CBD administration in combination with spinal cord stimulation (SCS) in FBSS patients… Expand
ConditionsFBSS
InterventionDrug
Opioids for neuropathic pain.
TLDR
The evidence derives from studies predominantly with features likely to overestimate treatment effects, i.e. small size, short duration, and potentially inadequate handling of dropouts, as well as randomized controlled trials in which opioid agonists were given to treat central or peripheral neuropathic pain of any etiology. Expand
Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms?
TLDR
Improving the current way of conducting clinical trials in NP could contribute to reduce therapeutic failures and may have an impact on future therapeutic algorithms. Expand
Memantine for the treatment of general neuropathic pain: a narrative review
TLDR
Two recent randomized trials showed significant efficacy of memantine: one demonstrated prophylactic effects against postoperative neuralgia and pain‐associated psychological impairment; in the other, memantine improved pain and cognition in fibromyalgia. Expand
Desipramine for neuropathic pain in adults.
TLDR
This review found little evidence to support the use of desipramine to treat neuropathic pain, but this came from studies that were methodologically flawed and potentially subject to major bias. Expand
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
TLDR
A meta-analysis involving 386 participants from two studies demonstrated modest, yet statistically significant, superiority of a gabapentin + opioid combination over gababentin alone, however, this combination also produced significantly more frequent side effect-related trial dropouts compared to gabAPentin alone. Expand
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
TLDR
The results support a revision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain and allow a strong recommendation for use and proposal as first-line treatment in neuropathicPain for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin. Expand
Imipramine for neuropathic pain in adults.
TLDR
This review found little evidence to support the use of imipramine to treat neuropathic pain, and suggested that effective medicines with much greater supportive evidence are available. Expand
Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons.
TLDR
Pregabalin and duloxetine had the largest beneficial effects for chronic peripheral neuropathic pain, and meta-analysis and indirect treatment comparisons inform best practice clinical decision-making. Expand
Interventions for Neuropathic Pain: An Overview of Systematic Reviews
TLDR
New randomized controlled trials about interventions for NeuP are necessary; they should address safety and use clear diagnostic criteria, and the majority of analyzed SRs were of medium quality. Expand
Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy
TLDR
Several factors that changed over time, such as larger study size, longer study duration, and more studies reporting 50% or 30% pain reduction, correlated with the decrease in estimated drug effect sizes suggest that issues related to the design, outcomes, and reporting have contributed to changes in the estimation of treatment effects. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 137 REFERENCES
Algorithm for neuropathic pain treatment : An evidence based proposal
New studies of the treatment of neuropathic pain have increased the need for an updated review of randomized, double-blind, placebocontrolled trials to support an evidence based algorithm to treatExpand
Pharmacologic management of neuropathic pain: Evidence-based recommendations
TLDR
Patients with neuropathic pain are challenging to manage and evidence‐based clinical recommendations for pharmacologic management are needed, and medications should be individualized, considering side effects, potential beneficial or deleterious effects on comorbidities, and whether prompt onset of pain relief is necessary. Expand
Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain.
TLDR
Lamotrigine (up to 400 mg/day) added to gabapentin, a tricyclic antidepressant, or a nonopioid analgesic did not demonstrate efficacy as an adjunctive treatment of neuropathic pain but was generally safe and well tolerated. Expand
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
TLDR
The objectives of the current article are to review the Neuropathic Pain Special Interest Group guidelines for the pharmacological management of neuropathic pain and to provide a brief overview of several recent clinical trials. Expand
Antidepressants for neuropathic pain.
TLDR
This update has provided additional confirmation on the effectiveness of antidepressants for neuropathic pain and has provided new information on another antidepressant - venlafaxine. Expand
What can we learn from failed neuropathic pain trials?
TLDR
Analysis of study characteristics of 105 clinical trials performed between 1966 and 2005 that were reported in a recent meta-analysis that focused on drug classes believed to have a treatment effect described factors that are associated with positive vs negative outcomes in placebo-controlled neuropathic pain trials and parallels to similar analyses of depression trials. Expand
Oral opioid therapy for chronic peripheral and central neuropathic pain.
TLDR
The reduction in the intensity of neuropathic pain was significantly greater during treatment with higher doses of opioids than with lower doses, and higher doses produced more side effects without significant additional benefit in terms of other outcome measures. Expand
Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial
TLDR
Smoked cannabis was generally well tolerated and effective when added to concomitant analgesic therapy in patients with medically refractory pain due to HIV DSPN. Expand
Pregabalin in patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen
TLDR
Pregabalin, in a flexible‐dose regime, produced clinically significant reductions in pain, as well as improvements in health status in patients suffering from severe central neuropathic pain. Expand
Emerging drugs in neuropathic pain
TLDR
In the interest of improving patient care, the authors recommend implementing comparative studies throughout the development process in order to demonstrate the increased value of novel agents. Expand
...
1
2
3
4
5
...